ClinicalTrials.gg
RecruitingNCT07864129SEPT-TOFUpdated Oct 7, 2026

Volution of Pulmonary Artery Dimensions in Tetralogy of Fallot

An observational study in Tetralogy of Fallot (TOF) and Congenital Heart Defects, sponsored by University Hospital, Strasbourg, France. Recruiting at 1 site in France. Open to participants aged 0 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by University Hospital, Strasbourg, France · Observational

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 5 months later.
Updated Oct 7, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Retrospective
Enrollment
400
Ages
0 Years to 18 Years
Sex
All
01

Study summary

Tetralogy of Fallot is the most common cyanotic congenital heart disease. Management strategies vary between primary repair and staged approaches including palliative surgery. The development of pulmonary arteries is a key determinant in surgical decision-making.

This multicenter retrospective observational study aims to evaluate the evolution of pulmonary artery dimensions using the Nakata index at key stages of patient management (birth, palliative surgery, and complete repair). The goal is to assess its predictive value in optimizing surgical strategy and improving outcomes in patients with Tetralogy of Fallot or pulmonary atresia with ventricular septal defect.

02

Conditions studied

  • Tetralogy of Fallot (TOF)
  • Congenital Heart Defects

Keywords

  • Tetralogy of Fallot
  • Pulmonary arteries
  • Nakata index
  • Congenital heart disease
  • Pediatric cardiology
03

In context

Tetralogy of Fallot

92 studies on the registry are indexed under Tetralogy of Fallot; 25 are open to participants now.

This study's planned enrollment of 400 is above the median of 150 across 40 observational studies indexed under Tetralogy of Fallot.

Browse Tetralogy of Fallot studies →

Lead sponsor

University Hospital, Strasbourg, France is the lead sponsor of 1,000 studies on the registry; 359 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
0 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Pediatric patients with Tetralogy of Fallot or related conditions managed surgically in tertiary care centers in Strasbourg and Bordeaux.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged from birth to less than 18 years
  • Patients operated at Strasbourg or Bordeaux University Hospitals between 01/01/2010 and 31/12/2024
  • Patient (or legal guardians) not opposing the reuse of medical data for research purposes

Exclusion criteria

Exclusion Criteria:

  • Patient expressing opposition to participation in the study
  • Parents/legal guardians or minor opposing data reuse
  • Specific clinical forms (VDDI)
  • Absence of subvalvular obstruction and absence of muscular resection
05

Study design

Observational model
Case-only
Time perspective
Retrospective
Enrollment
400 participants (estimated)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Nakata index evolution and predictive value

    Assessment of the Nakata index based on pulmonary artery diameters measured on imaging at different time points (birth, palliative surgery, complete repair), and evaluation of its association with surgical outcomes using predefined thresholds (108 and 160 mm²/m²).

    Time frame: From birth to complete surgical repair (retrospective data 2010-2024)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Apr 2027, 10 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2026
First posted
Oct 7, 2026
StartActual
Jun 18, 2026
Primary completionEst.
Apr 18, 2027
CompletionEst.
Jun 18, 2027
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07864129
Responsible party
Sponsor
First posted
Oct 7, 2026
Start date
Jun 18, 2026
Primary completion
Apr 18, 2027 (estimated)
Completion
Jun 18, 2027 (estimated)
Last update
Oct 7, 2026

Study contacts

Laurent Bonnemains, MD, PhD
Contact
laurent.bonnemains@chru-strasbourg.fr
33 3 88 12 74 99

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion